Arvinas (ARVN)
(Delayed Data from NSDQ)
$26.16 USD
+0.12 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $26.15 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 201 - 213 ( 213 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Our Presenting Companies at the ROTH Conference and 2020 Catalyst Calendar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to 2020; Initial Efficacy Data 1H:2020; Raising PT to $60
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $35 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Earnings; Efficacy Data for ARV-110 Expected in 1H:20
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
First Look at PROTAC Clinical Data Provides Platform Validation
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
EMSO 2019 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $38 PT; Weapons of Selective Destruction
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R